vadimezan has been researched along with everolimus in 2 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 5,631 | 1,289 | 4,579 |
| Protein | Taxonomy | vadimezan (IC50) | everolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 2 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azabdaftari, G; Ellis, L; Hammers, H; Lehet, K; Pili, R; Seshadri, M; Shah, P; Sotomayor, P | 1 |
| Gevertz, JL | 1 |
2 other study(ies) available for vadimezan and everolimus
| Article | Year |
|---|---|
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antigens; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Everolimus; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Kidney Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Sirolimus; Spheroids, Cellular; TOR Serine-Threonine Kinases; Tumor Burden; Xanthones; Xenograft Model Antitumor Assays | 2012 |
Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Topics: Angiogenesis Inhibitors; Bevacizumab; Bibenzyls; Computer Simulation; Cytotoxins; Drug Combinations; Drug Dosage Calculations; Endothelial Cells; Everolimus; Humans; Models, Statistical; Neoplasms; Neovascularization, Pathologic; Tumor Microenvironment; Xanthones | 2016 |